1. Home
  2. PCRX vs MFIC Comparison

PCRX vs MFIC Comparison

Compare PCRX & MFIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PCRX
  • MFIC
  • Stock Information
  • Founded
  • PCRX 2006
  • MFIC 2004
  • Country
  • PCRX United States
  • MFIC United States
  • Employees
  • PCRX N/A
  • MFIC N/A
  • Industry
  • PCRX Biotechnology: Pharmaceutical Preparations
  • MFIC Finance/Investors Services
  • Sector
  • PCRX Health Care
  • MFIC Finance
  • Exchange
  • PCRX Nasdaq
  • MFIC Nasdaq
  • Market Cap
  • PCRX 1.2B
  • MFIC 1.4B
  • IPO Year
  • PCRX 2011
  • MFIC 2004
  • Fundamental
  • Price
  • PCRX $25.16
  • MFIC $14.60
  • Analyst Decision
  • PCRX Buy
  • MFIC Buy
  • Analyst Count
  • PCRX 9
  • MFIC 7
  • Target Price
  • PCRX $26.22
  • MFIC $14.67
  • AVG Volume (30 Days)
  • PCRX 805.4K
  • MFIC 302.7K
  • Earning Date
  • PCRX 02-27-2025
  • MFIC 02-25-2025
  • Dividend Yield
  • PCRX N/A
  • MFIC 10.41%
  • EPS Growth
  • PCRX N/A
  • MFIC 14.94
  • EPS
  • PCRX N/A
  • MFIC 1.53
  • Revenue
  • PCRX $694,957,000.00
  • MFIC $291,576,000.00
  • Revenue This Year
  • PCRX $5.55
  • MFIC $12.92
  • Revenue Next Year
  • PCRX $5.64
  • MFIC $17.11
  • P/E Ratio
  • PCRX N/A
  • MFIC $9.57
  • Revenue Growth
  • PCRX 4.40
  • MFIC 8.84
  • 52 Week Low
  • PCRX $11.16
  • MFIC $12.26
  • 52 Week High
  • PCRX $31.67
  • MFIC $16.36
  • Technical
  • Relative Strength Index (RSI)
  • PCRX 52.48
  • MFIC 72.87
  • Support Level
  • PCRX $25.41
  • MFIC $13.99
  • Resistance Level
  • PCRX $26.89
  • MFIC $14.74
  • Average True Range (ATR)
  • PCRX 1.18
  • MFIC 0.16
  • MACD
  • PCRX -0.36
  • MFIC 0.05
  • Stochastic Oscillator
  • PCRX 4.35
  • MFIC 86.27

About PCRX Pacira BioSciences Inc.

Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company has three commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve.

About MFIC MidCap Financial Investment Corporation

MidCap Financial Investment Corp is an externally managed, publicly traded, closed-end, diversified management investment company. Its investment objective is to generate current income and, to a lesser extent, long-term capital appreciation. It predominantly invests in directly originated and privately negotiated first lien senior secured loans to privately held U.S. middle-market companies, and in other types of securities including, first lien unitranche, second lien senior secured, unsecured, subordinated, and mezzanine loans, and equities in both private and public middle market companies.

Share on Social Networks: